RBC keeps USD 1,500.00 target for Eli Lilly stock

Published on 10/13/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 22.97 billion in second-quarter 2026. Eli Lilly stock costs EUR 1,051.40 on October 13, 2026, minus 0.44 percent versus Xetra close.

RBC target and earnings date

Royal Bank of Canada maintained its USD 1,500.00 target for Eli Lilly on October 12, 2026.
Revenue was USD 22.97 billion in the second quarter of 2026.
Eli Lilly stock costs EUR 1,051.40 at Lang & Schwarz on October 13, 2026 at 4:03 p.m. CEST, minus 0.44 percent versus the Xetra close of October 12, 2026.
Eli Lilly's next earnings call is scheduled for October 29, 2026.

Fotorealistischer Blick auf eine generische Plasma-Etch-Maschine mit lila Plasmaschein durch das Sichtfenster im Halbleiter-Reinraum — Lam Research US5324571083 generische Plasma Etch Maschine mit lila Plasma im modernen Reinraum sichtbar, Illustration mit AI erstellt.

Royal Bank of Canada reiterated its Outperform rating and maintained a USD 1,500.00 price target for Eli Lilly stock on October 12, 2026, according to MarketBeat. Against the USD 1,174.19 NYSE price at 10:09 a.m. ET on October 13, 2026, that target lies 27.75 percent higher. At Lang & Schwarz on October 13, 2026 at 4:03 p.m. CEST, Eli Lilly stock was trading at EUR 1,051.40, minus 0.44 percent versus the Xetra close of October 12, 2026 at EUR 1,056.00.

Revenue sets the earnings base

Eli Lilly generated USD 22.97 billion in revenue in the second quarter of 2026, according to Seeking Alpha. The company reported GAAP diluted earnings per share of USD 7.94 for that period, while adjusted earnings per share were USD 8.38.

The revenue figure gives the October 29 report a substantial comparison point. Eli Lilly and Company lists its third-quarter 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT.

Yearly range and trading volume

The NYSE price of USD 1,174.19 stood below the USD 1,292.65 52-week high and above the USD 783.85 low on October 13, 2026. The same quote showed 213,765 shares traded against an average volume of 2,466,264 shares.

On October 9, 2026, Eli Lilly reported new Phase 3b data on Taltz and Zepbound, as stated on the company's investor page. The announcement is one dated clinical-development reference, while the current market report centers on the analyst target and the October 29 earnings date.

Valuation before October 29

Eli Lilly had a market capitalization of USD 1.1 trillion, a P/E ratio of 39.40 and a dividend yield of 0.01 percent on October 13, 2026. The target maintained by Royal Bank of Canada is above the current NYSE quote, but the euro price remains below the October 12 Xetra close.

Comparison with peers

Eli Lilly and Co.: minus 0.44 percent, P/E 39.40, market capitalization USD 1.1 trillion.
Novo Nordisk (USD): minus 0.54 percent, P/E 9.79, market capitalization USD 170.4 billion.
Merck & Co. (USD): minus 1.24 percent, P/E 114.99, market capitalization USD 354.8 billion.

Trading stays below the Xetra close

The EUR 1,051.40 Lang & Schwarz price was 0.44 percent below the EUR 1,056.00 Xetra close of October 12, 2026 at 4:03 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.